22131 CAR-T Cell Therapy Rises to the Challenge: An Expert Clinical Consult on New Evidence & Best Practice in Driving Modern Cellular Therapies as a Standard of Care for Leukemia and Lymphoma
Do you know the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into the management of patients with hematologic malignancies? Within the past few years, the indications for CAR-T therapy in leukemic and lymphoid malignancies have expanded significantly and now include acute lymphoblastic leukemia and multiple types of non-Hodgkin’s lymphoma. These advances, driven by the use of CD19-directed cell therapy constructs, have spurred numerous ongoing investigations of existing CAR-T therapies in additional CD19-expressing leukemias and lymphomas (eg, chronic lymphocytic leukemia, small lymphocytic lymphoma). Unfortunately, many hematology-oncology and bone marrow transplant BMT professionals have not adapted their practice to reflect the reality of cellular therapy in 2022—from the availability of new constructs with recent regulatory approvals to the management of practical considerations, such as referrals to specialized centers, appropriate follow-up, and toxicity management.
This video-based activity from PeerView will deliver expert guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in a variety of settings. The panelists will draw on personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, including enrollment of eligible patients in clinical trials testing the next steps with CAR-T therapy.
This activity can be accessed using the following URL: www.peerview.com/DRW
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, BMT nurse specialists, and other clinicians involved in the care of patients with relapsed/refractory leukemia and lymphoma.
Upon completion of this activity, participants should be better able to:
- Identify patients with leukemia or lymphoma who are eligible for and may benefit from CAR-T therapy based on current indications, clinical evidence, guideline recommendations, and clinical trial opportunities
- Implement best practices for integrating CAR-T therapy into the care of patients with leukemia or lymphoma, including referral to specialized treatment centers, clinical trial enrollment, and provision of post-treatment follow-up care
- Utilize appropriate AE management strategies for patients with relapsed/refractory leukemia or lymphoma who are experiencing toxicity while receiving CAR-T therapy, including cytokine release syndrome or neurotoxicity
In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Chair & Presenter
Michael R. Bishop, MD
Director, The David and Etta Jonas Center for Cellular Therapy
Section of Hematology/Oncology
University of Chicago
Michael R. Bishop, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Autolus Ltd; Bristol Myers Squibb; CRISPR Therapeutics; Iovance Biotherapeutics; Kite Pharma/Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation; and SANA Biotechnology.
Speakers Bureau participant with Agios Pharmaceuticals, Inc.; Bristol Myers Squibb; Incyte Corporation; and Kite Pharma/Gilead Sciences, Inc.; and Sanofi US.
Shannon L. Maude, MD, PhD
Cancer Immunotherapy Program
The Children’s Hospital of Philadelphia
Assistant Professor of Pediatrics
Medical Director, Center for Cellular Immunotherapies
Perelman School of Medicine at the University of Pennsylvania
Shannon L. Maude, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Novartis Pharmaceuticals Corporation and Wugen.
Grant/Research Support from Novartis Pharmaceuticals Corporation.
Other Financial or Material Support from Novartis Pharmaceuticals Corporation for speaking or teaching.
Peter A. Riedell, MD
Assistant Professor of Medicine
Director of Clinical Research, Hematopoietic Cellular Therapy Program
Associate Director, The David and Etta Jonas Center for Cellular Therapy
Section of Hematology/Oncology
University of Chicago
Peter A. Riedell, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for BeiGene; Celgene Corporation/Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Karyopharm Therapeutics; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceuticals U.S.A., Inc..
Grant/Research Support from Calibr; Celgene Corporation/Bristol Myers Squibb; Kite Pharma/Gilead Sciences, Inc.; MorphoSys US Inc.; Novartis Pharmaceuticals Corporation; Tessa Therapeutics Ltd.; and Xencor, Inc..
Speakers Bureau participant with Bayer Corporation and Kite Pharma/Gilead Sciences, Inc.
Paige Davies, PhD
PVI, PeerView Institute for Medical Education
Paige Davies, PhD, has no financial interests/relationships or affiliations in relation to this activity.
The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is co-provided with our educational partner, PVI, PeerView Institute for Medical Education.
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.